Stock 6733 BIOGEND THERAPEUTICS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials BioGend Therapeutics Co., Ltd.

Equities

6733

TW0006733009

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 23:00:00 27/05/2024 BST 		5-day change 1st Jan Change
36.15 TWD -0.96% Intraday chart for BioGend Therapeutics Co., Ltd. -3.60% -5.49%
05-28 BioGend Therapeutics Co., Ltd. Announces Hsinchu Factory Pass the Domestic Medical Device Quality Management System Manufacturing License CI
05-10 BioGend Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2020 2022 2023 2024
Capitalization 1 3,574 2,247 4,708 4,449
Enterprise Value (EV) 1 3,574 2,247 4,708 4,449
P/E ratio -23.3 x -12.2 x - -
Yield - - - -
Capitalization / Revenue - - 55.3 x 29.7 x
EV / Revenue - - 55.3 x 29.7 x
EV / EBITDA - - - -
EV / FCF - - - -63.6 x
FCF Yield - - - -1.57%
Price to Book - - - -
Nbr of stocks (in thousands) 92,000 103,076 123,076 123,076
Reference price 2 38.85 21.80 38.25 36.15
Announcement Date 15/03/21 29/03/23 02/03/24 -
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2022 2023 2024
Net sales 1 - - 85.06 150
EBITDA - - - -
EBIT 1 - - -159.9 -143
Operating Margin - - -188.02% -95.33%
Earnings before Tax (EBT) - - - -
Net income -145.6 -184.5 - -
Net margin - - - -
EPS -1.670 -1.790 - -
Free Cash Flow 1 - - - -70
FCF margin - - - -46.67%
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 15/03/21 29/03/23 02/03/24 -
1TWD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q4 2023 Q3 2023 Q4
Net sales 1 - - 14.73
EBITDA - - -
EBIT 1 - - -23.7
Operating Margin - - -160.92%
Earnings before Tax (EBT) - - -
Net income -53.32 -42.37 -
Net margin - - -
EPS -0.5200 -0.3600 -
Dividend per Share - - -
Announcement Date 29/03/23 06/11/23 02/03/24
1TWD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2022 2023 2024
Net Debt - - - -
Net Cash position - - - -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow 1 - - - -70
ROE (net income / shareholders' equity) - - - -23.5%
ROA (Net income/ Total Assets) - - - -23%
Assets - - - -
Book Value Per Share - - - -
Cash Flow per Share - - - -
Capex 1 - - - 5
Capex / Sales - - - 3.33%
Announcement Date 15/03/21 29/03/23 02/03/24 -
1TWD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
36.15 TWD
Average target price
48 TWD
Spread / Average Target
+32.78%
Consensus

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BIOGEND THERAPEUTICS CO., LTD. Stock BioGend Therapeutics Co., Ltd.
-5.49% 138M
MODERNA, INC. Stock Moderna, Inc.
+54.05% 58.71B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.02% 41.31B
LONZA GROUP AG Stock Lonza Group AG
+36.78% 39.2B
CELLTRION, INC. Stock Celltrion, Inc.
-10.22% 27.4B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.42% 26.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.60% 18.98B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+2.89% 12.51B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+22.40% 11.94B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.49% 12.08B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 6733 Stock
  4. Financials BioGend Therapeutics Co., Ltd.